As part of an interim management statement, Skyepharma has said that the launch of its Flutiform fluticasone/formoterol MDI in Spain could take place by the end of 2014, triggering a milestone payment of €2.0 million. The company also noted that it has received a €3.0 million milestone payment for the launch of the product in France in the first quarter of 2014.
In addition, the company said, it expects that its partner Kyorin Pharmaceutical will launch a 120-puff version of Flutiform in Japan in December of this year. Kyorin began marketing a 56-puff version in Japan in November 2013.
Also, according to Skyepharma, Argentine authorities have approved Sanofi’s application to market Flutiform, and Sanofi has filed an application in Colombia. Sanofi acquired a license to market Flutiform in Central and South America in 2011.
Read the Skyepharma interim management statement.
